Early Breast Cancer: 5 Years Versus 3 Years of Adjuvant Bisphosphonate Treatment

Description

The optimal duration of treatment using bisphosphonate for patients with early breast cancer is still unclear. In the phase III SUCCESS trial, Thomas W.P. Friedl, PhD, and colleagues from University Hospital Ulm, Prittwitzstr, Ulm, Germany, found there was no statistically significant difference in survival outcomes between 5 and 2 years of adjuvant zoledronate treatment. Their results were reported in JAMA Oncology.